Sign inJoin waitlistJoin the waitlist

Lyndsay Willmott

Assistant Professor, Obstetrics & Gynecology · University of Arizona College of Medicine - Phoenix

Credentials: · · · · ·

History

University of Arizona College of Medicine - Phoenix
Present
Creighton University School of Medicine
Present

Gynecologic Oncology
University of Rochester Medicine
2007–2010
Obstetrics and Gynecology
University of Rochester Medicine
2003–2007
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
1999–2003

Research

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Journal of Clinical Oncology · 2021 · 336 citations
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
Annals of Oncology · 2024 · 109 citations
Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture
Angiogenesis · 2010 · 90 citations

Bradley Monk
11 papers
Bhavana Pothuri
8 papers
Dana Chase
8 papers
Sudarshan Sharma
7 papers
JB
Joseph Buscema
6 papers
Brian Slomovitz
5 papers
Carolyn McCourt
5 papers
David O'Malley
5 papers
Kari Ring
5 papers
Matthew Powell
5 papers
Michael Gold
5 papers
RC
Robert Coleman
5 papers

Clinical trials

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Study of ACR-2316 in Specific Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Acrivon Therapeutics
2024–2027
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Site PI · Recruiting · Phase 3
Verastem, Inc.
2024–2031
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Site PI · Recruiting · Phase 2
Acrivon Therapeutics
2022–2027